These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24685872)

  • 1. Interstitial granulomatous drug reaction due to febuxostat.
    Laura A; Luca P; Luisa PA
    Indian J Dermatol Venereol Leprol; 2014; 80(2):182-4. PubMed ID: 24685872
    [No Abstract]   [Full Text] [Related]  

  • 2. Fixed drug eruption-like macules caused by febuxostat.
    Oda T; Sawada Y; Ohmori S; Omoto D; Haruyama S; Yoshioka M; Nishio D; Nakamura M
    Eur J Dermatol; 2016 Aug; 26(4):412-3. PubMed ID: 27211520
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Febuxostat--treatment for hyperuricemia and gout?
    Moreland LW
    N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
    [No Abstract]   [Full Text] [Related]  

  • 7. Allopurinol-induced drug reaction with eosinophilia and systemic symptoms syndrome with recurrence.
    Yang DC; Chang CM
    J Am Geriatr Soc; 2010 Oct; 58(10):2043-4. PubMed ID: 20929487
    [No Abstract]   [Full Text] [Related]  

  • 8. Allopurinol-induced palisaded neutrophilic and granulomatous dermatitis.
    Gordon K; Miteva M; Torchia D; Romanelli P
    Cutan Ocul Toxicol; 2012 Dec; 31(4):338-40. PubMed ID: 22250812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Febuxostat for prevention of gout attacks.
    Pohar S; Murphy G
    Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urate-lowering therapy for gout: focus on febuxostat.
    Love BL; Barrons R; Veverka A; Snider KM
    Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rhabdomyolysis associated with initiation of febuxostat therapy for hyperuricaemia in a patient with chronic kidney disease.
    Kang Y; Kim MJ; Jang HN; Bae EJ; Yun S; Cho HS; Chang SH; Park DJ
    J Clin Pharm Ther; 2014 Jun; 39(3):328-30. PubMed ID: 24612195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal function in gout: long-term treatment effects of febuxostat.
    Whelton A; Macdonald PA; Zhao L; Hunt B; Gunawardhana L
    J Clin Rheumatol; 2011 Jan; 17(1):7-13. PubMed ID: 21169856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in kidney transplant recipients.
    Tojimbara T; Nakajima I; Yashima J; Fuchinoue S; Teraoka S
    Transplant Proc; 2014; 46(2):511-3. PubMed ID: 24656001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
    Becker MA; MacDonald PA; Hunt B; Gunawardhana L
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1011-7. PubMed ID: 22132950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
    Prescrire Int; 2009 Apr; 18(100):63-5. PubMed ID: 19585722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Febuxostat: a new treatment for hyperuricaemia in gout.
    Edwards NL
    Rheumatology (Oxford); 2009 May; 48 Suppl 2():ii15-ii19. PubMed ID: 19447778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatal allopurinol-induced hypersensitivity syndrome associated with pancreatic abnormalities.
    Fathallah N; Ben Salem C; Slim R; Kaabia N; Letaief A; Bouraoui K
    J Clin Rheumatol; 2010 Jun; 16(4):170-1. PubMed ID: 20511977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Febuxostat (Uloric) for chronic treatment of gout.
    Med Lett Drugs Ther; 2009 May; 51(1312):37-8. PubMed ID: 19448587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
    Stevenson M; Pandor A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease.
    Kobayashi S; Ogura M; Hosoya T
    J Clin Pharm Ther; 2013 Jun; 38(3):258-61. PubMed ID: 23506426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.